OBJECTIVES: This study examined longitudinal trends in use of highly active antiretroviral therapy (HAART) among a cohort of HIV-positive participants in the Women' Interagency HIV Study. METHODS: Beginning in 1994, 1690 HIV-positive women reported detailed information about their use of antiretroviral therapy at 6-month study visits. Multivariate logistic and Cox regression analyses were used to estimate the likelihood of antiretroviral therapy and HAART use among women with study visits preceding and following HAART availability. RESULTS: Before the availability of HAART, the cohort' likelihood of any antiretroviral therapy use was associated with clinical indicators (CD4 count, viral load, symptom presence) as well as behavioral factors (abstaining from drug and alcohol use, participating in clinical trials). After HAART became commercially available, newly emerging predictors included college education, private insurance, absence of injection drug use history, and not being African American. CONCLUSIONS: After the penetration of HAART into this cohort, additional differences emerged between HAART users and nonusers. These findings can inform public health efforts to enhance women' access to the most effective types of therapy.
OBJECTIVES: This study examined longitudinal trends in use of highly active antiretroviral therapy (HAART) among a cohort of HIV-positive participants in the Women' Interagency HIV Study. METHODS: Beginning in 1994, 1690 HIV-positive women reported detailed information about their use of antiretroviral therapy at 6-month study visits. Multivariate logistic and Cox regression analyses were used to estimate the likelihood of antiretroviral therapy and HAART use among women with study visits preceding and following HAART availability. RESULTS: Before the availability of HAART, the cohort' likelihood of any antiretroviral therapy use was associated with clinical indicators (CD4 count, viral load, symptom presence) as well as behavioral factors (abstaining from drug and alcohol use, participating in clinical trials). After HAART became commercially available, newly emerging predictors included college education, private insurance, absence of injection drug use history, and not being African American. CONCLUSIONS: After the penetration of HAART into this cohort, additional differences emerged between HAART users and nonusers. These findings can inform public health efforts to enhance women' access to the most effective types of therapy.
Authors: W E Cunningham; R M Andersen; M H Katz; M D Stein; B J Turner; S Crystal; S Zierler; K Kuromiya; S C Morton; P St Clair; S A Bozzette; M F Shapiro Journal: Med Care Date: 1999-12 Impact factor: 2.983
Authors: M F Shapiro; S C Morton; D F McCaffrey; J W Senterfitt; J A Fleishman; J F Perlman; L A Athey; J W Keesey; D P Goldman; S H Berry; S A Bozzette Journal: JAMA Date: 1999 Jun 23-30 Impact factor: 56.272
Authors: S E Barkan; S L Melnick; S Preston-Martin; K Weber; L A Kalish; P Miotti; M Young; R Greenblatt; H Sacks; J Feldman Journal: Epidemiology Date: 1998-03 Impact factor: 4.822
Authors: Tracey E Wilson; Mary Elizabeth Gore; Ruth Greenblatt; Mardge Cohen; Howard Minkoff; Sylvia Silver; Esther Robison; Alexandra Levine; Stephen J Gange Journal: Am J Public Health Date: 2004-07 Impact factor: 9.308
Authors: Rita M Melendez; Theresa A Exner; Anke A Ehrhardt; Brian Dodge; Robert H Remien; Mary-Jane Rotheram-Borus; Marguerita Lightfoot; Daniel Hong Journal: Am J Public Health Date: 2005-08-30 Impact factor: 9.308
Authors: Melanie C Bacon; Viktor von Wyl; Christine Alden; Gerald Sharp; Esther Robison; Nancy Hessol; Stephen Gange; Yvonne Barranday; Susan Holman; Kathleen Weber; Mary A Young Journal: Clin Diagn Lab Immunol Date: 2005-09
Authors: David N Feldman; Joseph G Feldman; Ruth Greenblatt; Kathryn Anastos; Leigh Pearce; Mardge Cohen; Stephen Gange; Suzanne Leanza; Robbie Burk Journal: AIDS Educ Prev Date: 2009-06
Authors: Panagiotis Dragonas; Linda M Kaste; Martha Nunn; Praveen K Gajendrareddy; Kathleen M Weber; Mardge Cohen; Oluwatoyin M Adeyemi; Audrey L French; Herve Y Sroussi Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Date: 2018-02-19
Authors: Daniel J Merenstein; Michael F Schneider; Christopher Cox; Rebecca Schwartz; Kathleen Weber; Esther Robison; Monica Gandhi; Jean Richardson; Michael W Plankey Journal: Pediatrics Date: 2008-04 Impact factor: 7.124
Authors: Aaron J Blashill; Kenneth H Mayer; Heidi Crane; Jessica F Magidson; Chris Grasso; W Christopher Mathews; Michael S Saag; Steven A Safren Journal: Ann Behav Med Date: 2013-10
Authors: Michael J Silverberg; Mary Elizabeth Gore; Audrey L French; Monica Gandhi; Marshall J Glesby; Andrea Kovacs; Tracey E Wilson; Mary A Young; Stephen J Gange Journal: Clin Infect Dis Date: 2004-08-16 Impact factor: 9.079
Authors: Elizabeth Kiefer; Donald R Hoover; Qiuhu Shi; Mark H Kuniholm; Michael Augenbraun; Mardge H Cohen; Elizabeth T Golub; Robert C Kaplan; Chenglong Liu; Marek Nowicki; Phyllis C Tien; Russell P Tracy; Kathryn Anastos Journal: J Acquir Immune Defic Syndr Date: 2014-11-01 Impact factor: 3.731